vs
Axil Brands, Inc.（AXIL）与Journey Medical Corp（DERM）财务数据对比。点击上方公司名可切换其他公司
Journey Medical Corp的季度营收约是Axil Brands, Inc.的2.0倍（$16.1M vs $8.1M），Axil Brands, Inc.净利率更高（8.7% vs -7.8%，领先16.4%），Journey Medical Corp同比增速更快（27.3% vs 5.2%），过去两年Axil Brands, Inc.的营收复合增速更高（12.1% vs 11.0%）
Axil Brands是一家总部位于美国的专业消费电子企业，主营高端听力防护设备、音频增强装置及个性化音频配件，旗下产品涵盖定制耳塞、运动蓝牙耳机等，面向全球普通消费者及专业作业群体销售。
Journey Medical Corp是一家处于商业化阶段的生物制药企业，专注于皮肤病治疗领域，研发、生产并销售处方及非处方皮肤用药，覆盖痤疮、特应性皮炎、皮肤真菌感染等适应症，主要服务美国市场的医疗机构与患者。
AXIL vs DERM — 直观对比
营收规模更大
DERM
是对方的2.0倍
$8.1M
营收增速更快
DERM
高出22.1%
5.2%
净利率更高
AXIL
高出16.4%
-7.8%
两年增速更快
AXIL
近两年复合增速
11.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.1M | $16.1M |
| 净利润 | $704.9K | $-1.2M |
| 毛利率 | 68.1% | — |
| 营业利润率 | 11.1% | -2.8% |
| 净利率 | 8.7% | -7.8% |
| 营收同比 | 5.2% | 27.3% |
| 净利润同比 | 11.2% | -182.0% |
| 每股收益（稀释后） | $0.09 | $-0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXILDERM
| Q4 25 | $8.1M | $16.1M | ||
| Q3 25 | $6.9M | $17.0M | ||
| Q2 25 | $5.8M | $15.0M | ||
| Q1 25 | $6.9M | $13.1M | ||
| Q4 24 | $7.7M | $12.6M | ||
| Q3 24 | $5.9M | $14.6M | ||
| Q2 24 | $6.5M | $14.9M | ||
| Q1 24 | $6.5M | $13.0M |
净利润AXILDERM
| Q4 25 | $704.9K | $-1.2M | ||
| Q3 25 | $334.3K | $-2.3M | ||
| Q2 25 | $-245.6K | $-3.8M | ||
| Q1 25 | $576.7K | $-4.1M | ||
| Q4 24 | $633.7K | $1.5M | ||
| Q3 24 | $-109.8K | $-2.4M | ||
| Q2 24 | $49.5K | $-3.4M | ||
| Q1 24 | $781.1K | $-10.4M |
毛利率AXILDERM
| Q4 25 | 68.1% | — | ||
| Q3 25 | 67.6% | — | ||
| Q2 25 | 70.0% | — | ||
| Q1 25 | 71.7% | — | ||
| Q4 24 | 71.1% | 82.3% | ||
| Q3 24 | 71.0% | 63.9% | ||
| Q2 24 | 71.5% | 56.0% | ||
| Q1 24 | 71.5% | 47.7% |
营业利润率AXILDERM
| Q4 25 | 11.1% | -2.8% | ||
| Q3 25 | 6.0% | -9.0% | ||
| Q2 25 | 0.8% | -19.2% | ||
| Q1 25 | 8.4% | -25.3% | ||
| Q4 24 | 8.7% | 17.7% | ||
| Q3 24 | -2.4% | -19.8% | ||
| Q2 24 | 2.6% | -19.7% | ||
| Q1 24 | -1.6% | -77.4% |
净利率AXILDERM
| Q4 25 | 8.7% | -7.8% | ||
| Q3 25 | 4.9% | -13.6% | ||
| Q2 25 | -4.3% | -25.3% | ||
| Q1 25 | 8.3% | -31.0% | ||
| Q4 24 | 8.2% | 12.1% | ||
| Q3 24 | -1.9% | -16.3% | ||
| Q2 24 | 0.8% | -22.6% | ||
| Q1 24 | 12.1% | -80.1% |
每股收益（稀释后）AXILDERM
| Q4 25 | $0.09 | $-0.04 | ||
| Q3 25 | $0.04 | $-0.09 | ||
| Q2 25 | $-0.03 | $-0.16 | ||
| Q1 25 | $0.07 | $-0.18 | ||
| Q4 24 | $0.08 | $0.10 | ||
| Q3 24 | $-0.02 | $-0.12 | ||
| Q2 24 | $0.11 | $-0.17 | ||
| Q1 24 | $0.04 | $-0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.0M | $24.1M |
| 总债务越低越好 | $138.3K | $25.3M |
| 股东权益账面价值 | $11.1M | $31.9M |
| 总资产 | $16.2M | $94.6M |
| 负债/权益比越低杠杆越低 | 0.01× | 0.79× |
8季度趋势，按日历期对齐
现金及短期投资AXILDERM
| Q4 25 | $5.0M | $24.1M | ||
| Q3 25 | $4.1M | $24.9M | ||
| Q2 25 | $4.8M | $20.3M | ||
| Q1 25 | $4.7M | $21.1M | ||
| Q4 24 | $5.2M | $20.3M | ||
| Q3 24 | $4.1M | $22.5M | ||
| Q2 24 | $3.3M | $23.9M | ||
| Q1 24 | $4.9M | $24.1M |
总债务AXILDERM
| Q4 25 | $138.3K | $25.3M | ||
| Q3 25 | $139.2K | $25.2M | ||
| Q2 25 | $140.2K | $25.1M | ||
| Q1 25 | $141.0K | $25.0M | ||
| Q4 24 | $143.3K | $24.9M | ||
| Q3 24 | $144.3K | $19.8M | ||
| Q2 24 | $146.6K | $19.7M | ||
| Q1 24 | — | $14.7M |
股东权益AXILDERM
| Q4 25 | $11.1M | $31.9M | ||
| Q3 25 | $10.2M | $25.9M | ||
| Q2 25 | $9.7M | $19.2M | ||
| Q1 25 | $9.7M | $21.5M | ||
| Q4 24 | $8.8M | $20.1M | ||
| Q3 24 | $7.9M | $10.9M | ||
| Q2 24 | $7.7M | $11.3M | ||
| Q1 24 | $8.8M | $13.0M |
总资产AXILDERM
| Q4 25 | $16.2M | $94.6M | ||
| Q3 25 | $15.4M | $85.2M | ||
| Q2 25 | $12.9M | $81.2M | ||
| Q1 25 | $13.0M | $85.0M | ||
| Q4 24 | $13.7M | $80.2M | ||
| Q3 24 | $11.4M | $64.0M | ||
| Q2 24 | $11.0M | $65.2M | ||
| Q1 24 | $12.7M | $66.6M |
负债/权益比AXILDERM
| Q4 25 | 0.01× | 0.79× | ||
| Q3 25 | 0.01× | 0.97× | ||
| Q2 25 | 0.01× | 1.30× | ||
| Q1 25 | 0.01× | 1.16× | ||
| Q4 24 | 0.02× | 1.24× | ||
| Q3 24 | 0.02× | 1.81× | ||
| Q2 24 | 0.02× | 1.75× | ||
| Q1 24 | — | 1.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $934.8K | $-6.3M |
| 自由现金流经营现金流 - 资本支出 | $906.4K | — |
| 自由现金流率自由现金流/营收 | 11.1% | — |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | 1.33× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AXILDERM
| Q4 25 | $934.8K | $-6.3M | ||
| Q3 25 | $-739.2K | $-2.4M | ||
| Q2 25 | $194.4K | $-942.0K | ||
| Q1 25 | $-169.9K | $-2.8M | ||
| Q4 24 | $1.0M | $2.2M | ||
| Q3 24 | $897.3K | $-1.2M | ||
| Q2 24 | $-336.6K | $-5.2M | ||
| Q1 24 | $-912.8K | $-5.0M |
自由现金流AXILDERM
| Q4 25 | $906.4K | — | ||
| Q3 25 | $-747.6K | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-258.2K | — | ||
| Q4 24 | $941.1K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-394.9K | — | ||
| Q1 24 | $-922.1K | — |
自由现金流率AXILDERM
| Q4 25 | 11.1% | — | ||
| Q3 25 | -10.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -3.7% | — | ||
| Q4 24 | 12.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.1% | — | ||
| Q1 24 | -14.3% | — |
资本支出强度AXILDERM
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 0.1% | — |
现金转化率AXILDERM
| Q4 25 | 1.33× | — | ||
| Q3 25 | -2.21× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.29× | — | ||
| Q4 24 | 1.59× | 1.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.80× | — | ||
| Q1 24 | -1.17× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXIL
| Hearing Enhancement And Protection | $7.8M | 95% |
| Other | $378.9K | 5% |
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
